Home  |  News  | Member Log In    Twitter Facebook   
 

Mission

NEHI is dedicated to transforming health care for the benefit of patients and their families.

Who we are

NEHI is a nonprofit, health policy institute focused on enabling innovation that will improve health care quality and lower health care costs. Working in partnership with members from across the health care system, NEHI brings an objective, collaborative and fresh voice to health policy. We combine the collective vision of our diverse membership and our independent, evidence-based research to move ideas into action.

How we’re different

NEHI is not a trade organization or typical think tank. We represent all sectors of health care and use our research to move ideas into action. As an independent, coalition-building entity, we find mutual solutions to mutual problems facing health care. We are the largest, most diverse, multi-stakeholder health care organization in the nation.

Visit the press room to review our media kit.

Learn how to become a member or support NEHI programs in other ways.

Board of Directors

John Fallon, MD (Chair)

Chief Physician Executive, Blue Cross Blue Shield of Massachusetts

John has been the Chief Physician Executive and Senior Vice President at Blue Cross Blue Shield of Massachusetts for over eight years. He is responsible for ensuring the highest standards of medical care for its members. He is also accountable for helping expand health care strategies involving quality, effectiveness, efficiency and their relationships to new payment methodologies. He oversees the company’s medical policies, acts as the main liaison with the plan’s provider network, reviews upcoming legislation for medical impact, manages the company’s medical directors, acts as primary spokesperson for medical inquires and is the main medical contact with the National Blue Cross Blue Shield Association and its 39 plans across the country, covering almost 100 million members.

Prior to coming to BCBSMA, he was CEO for the entire clinical enterprise at the State University of New York’s Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. He still maintains his academic appointment as Clinical Professor in the Graduate Program of Public Health. His professional experiences also include the Partners Healthcare System, where he was Chairman of the physician network. He was also the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts. He is Chair of the National Council of Physician Executives at the Blue Cross Blue Shield Association.

He serves on many boards; locally, among them are NEHI (Chair), nationally NCQA Medical Standards (Chair), New England Comparative Effectiveness Public Advisory Council (CEPAC) and Temple University School of Medicine Board of Advisors. John practiced Internal Medicine for over 20 years; did his residency at Boston City Hospital; is Board Certified in Internal Medicine; and is a Fellow of the American College of Physicians.

Joshua Boger, PhD (Chairs Emeriti)

Founder & Chief Executive Officer (retired), Vertex Pharmaceuticals, Inc.

Joshua Boger is the founder of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and retired as CEO in May 2009. Prior to founding Vertex in 1989, he worked for more than a decade in pharmaceutical research at Merck, where he developed an international reputation as a leader in the application of computer modeling to the chemistry of drug design and was a pioneer in the use of structure-based rational drug design as the basis for drug discovery programs. He holds a bachelor of arts in Chemistry and Philosophy from Wesleyan University (Connecticut) and a master's and doctorate degrees in Chemistry from Harvard University. He is the author of over 50 scientific publications, holds 31 issued U.S. patents in pharmaceutical discovery and development, and has lectured widely in the United States, in Europe and in Asia on various aspects of drug discovery, development and commercialization.

He is the Chairs Emeriti of the New England Healthcare Institute, Chairman of the Board of Trustees at Wesleyan University (Middletown, CT), Vice-Chair of the Board of Fellows of the Harvard Medical School, Co-Chairman of the Progressive Business Leaders Network (a non-profit, non-partisan business organization) and Chair of the Board of the Celebrity Series (Boston’s premier performing arts series).

He serves on several additional Boards including the Biotechnology Industry Organization (BIO, where he is Immediate-Past-Chairman), the Harvard Board of Overseers, The Hastings Center (the leading independent bioethics research institute, located in Garrison, NY), the American Civil Liberties Union of Massachusetts Foundation, the Science Advisory Council of WGBH (public broadcasting’s leading station, Boston), the Museum of Science (Boston), the Massachusetts Workforce Investment Board, the Massachusetts Life Sciences Center, the Dean’s Advisory Group of the Harvard School of Engineering and Applied Sciences, the Harvard College Overseers’ Committee to Visit the Business School and the MIT Corporation Visiting Committees to the Department of Biology and to Whitaker College/Health Sciences & Technology (HST).

Joseph B. Martin, MD, PhD (Chairs Emeriti)

Lefler Professor of Neurobiology and Dean Emeritus, Harvard Medical School

Joseph B. Martin, M.D., Ph.D. was appointed the Edward R. and Anne G. Lefler Professor of Neurobiology at Harvard Medical School in July 2007.

Prior to this appointment, Dr. Martin served for ten years as Dean of the Faculty of Medicine at Harvard University. At Harvard, he helped establish, in 1999, the Dana-Farber/Harvard Cancer Center, and in 2001, with the support of an anonymous donor, Dr. Martin formed the Harvard center for Neurodegeneration and Repair, dedicated to understanding the prevention, causes, and treatment of neurodegenerative diseases. In 2003, Dr. Martin dedicated Harvard Medical School's New Research Building, which is designed to cultivate scientific collaboration between the basic and clinical sciences.

From 1989-1993 Dr. Martin served for four years as Dean of the School of Medicine at UCSF. During his tenure as Dean, he established the W.M. Keck Foundation Center for Integrative Neurosciences, the Gladstone Institute for Virology and Immunology, and began planning for a Comprehensive Cancer Center. In 1993, he was appointed Chancellor of UCSF.

Dr. Martin served on the Faculty of Medicine at McGill University in Montreal from 1970-1978. Following his tenure at McGill, he was chief of the Neurology Service at Massachusetts General Hospital and Julieanne Dorn Professor of Neurology at HMS from 1978-1989. At the Massachusetts General Hospital, he led the development in neurogenetics of neurodegenerative disorders, leading to the discovery of the gene for HD.

Dr. Martin received his premedical and medical education at the University of Alberta, Edmonton, earning the M.D. degree in 1962. He completed a residency in neurology in 1966 and fellowship in neuropathology in 1967 at Case Western Reserve University in Cleveland, Ohio, and received his Ph.D. in anatomy from the University of Rochester in 1971.

Henri Termeer (Chairs Emeriti)

Former Chairman and CEO, Genzyme Corporation

Henri A. Termeer was appointed president of Genzyme Corporation in 1983, two years after the company's founding. He became its chief executive officer in 1985 and chairman in 1988. Under his leadership, Genzyme has grown from a modest entrepreneurial venture to one of the world's leading biotechnology companies, and in 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

Mr. Termeer is recognized as a pioneer in developing and delivering treatments to patients with rare genetic diseases around the world. He is a trustee for the Boston Museum of Science, a member of the Massachusetts Institute of Technology Corporation and a member of the board of directors of Project HOPE, an international nonprofit health education and humanitarian assistance organization.

Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer serves on the board of directors of both the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America. He is a director of Massachusetts General Hospital and is a member of the board of fellows of Harvard Medical School. In addition, Mr. Termeer is deputy chairman of the Federal Reserve Bank of Boston's board of directors and a member of the board of directors of Abiomed Inc. He was also instrumental in founding the New England Healthcare Institute.

A Native of the Netherlands, Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden School at the University of Virginia.

Harris A. Berman, MD (Vice Chair)

Dean, Tufts University School of Medicine

Harris A. Berman, MD is dean at the Tufts University School of Medicine. Dr. Berman served as the dean ad interim since 2009. Prior to that, he was Dean of Public Health and Professional Degree Programs and Chair of the Department of Public Health and Community Medicine. Before coming to Tufts University he was a pioneer in the development of managed care in New England, and for 17 years, the CEO of the Tufts Health Plan.

Before joining Tufts Health Plan, Dr. Berman co-founded the Matthew Thornton Health Plan in Nashua, NH, one of the first HMOs in New England. He has served as chairman of the board of the Massachusetts Association of HMOs, and of the Bank of America Celebrity Series. He has also served as a director of the American Association of Health Plans and of Tufts Medical Center. Dr. Berman has international experience as a Peace Corps Physician in India and a consultant to the U.S. Agency for International Development in several international projects. At Tufts, he has spearheaded the expansion of the Global Health Program.

A graduate of Harvard College and Columbia University College of Physicians and Surgeons, Dr. Berman served as a resident on the Harvard Medical Service of Boston City Hospital and at Tufts-New England Medical Center, and an Infectious Disease fellowship at Tufts-New England Medical Center. He is a F ellow of the American College of Physicians.

Jonathan Fleming (Treasurer)

Managing Partner, Oxford Bioscience Partners

Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut.

Mr. Fleming has been in the investment business for over twenty years, starting and financing growth companies in the United States, Europe, and Israel. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming holds a Master’s degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.

Mr. Fleming is a co-founder and Chairman of the Board of Memory Pharmaceuticals (NASDAQ: MEMY). He is also Chairman of the Board of BioProcessors Corporation and is a director of several private companies including Leerink Swann, a Boston based investment bank specializing in healthcare companies. Mr. Fleming is a Trustee of the Museum of Science in Boston and a Senior Lecturer at the MIT Sloan School of Business.

Nick Littlefield (Vice Chair)

Partner, Foley Hoag, LLP

Nick Littlefield, Partner and Co-Chair, Government Strategies Group, at Foley Hoag LLP, concentrates his practice in the areas of biotechnology, biomedical research and health care technology. He specializes in regulatory, administrative and legislative issues for large and small companies, non profit organizations and trade associations. Mr. Littlefield and his colleagues in the Foley Hoag Life Sciences Group work from offices in Boston and Washington. For nine years until 1998, Mr. Littlefield served as Staff Director and Chief Counsel for Massachusetts Senator Edward M. Kennedy on the United States Senate Health, Education, Labor and Pensions Committee, where he worked extensively on biomedical research, health policy, and life sciences regulatory and legislative initiatives. Previously, he taught at Harvard Law School and was an Assistant United States Attorney in the Southern District of New York. He is a graduate of Harvard College and the University of Pennsylvania Law School.

Beverly Lorell, MD (Clerk)

Senior Medical and Policy Advisor, FDA/Healthcare Practice Group, King & Spalding, LLP

Beverly H. Lorell, M.D. is the Senior Medical and Policy Advisor with King & Spalding's FDA/Healthcare Practice Group in Washington, D.C. Dr. Lorell specializes in the areas of clinical trial design of studies for drugs, devices and biologics; review of pre-market submissions; recalls; and assessment of matters involving a risk to health. She also specializes in the area of physician and industry relations and the development of independent scientific panels to advise health industries.

Dr. Lorell, who was previously Professor of Medicine at Harvard University, has over twenty-five years of experience as a practicing interventional cardiologist and heart failure specialist. She is an internationally recognized clinical and basic science investigator with extensive experience in multi-center clinical trials and preclinical proof-of-concept translational science. Prior to joining King & Spalding, Dr. Lorell served as Vice President and global Chief Medical and Technology Officer at Guidant Corporation. There her responsibilities included evaluating emerging technologies and attendant regulatory challenges, determining product development priorities, and influencing clinical research strategies. She participated in the firm's board for business development.

During her career at Harvard Medical School, she served the federal government in multiple roles including as a federally funded investigator of the National Institutes of Health and on the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee.

Dr. Lorell has served in national leadership positions in professional societies. She was an Established Investigator of the American Heart Association (AHA). Additional honors include election as Fellow of the American College of Cardiology (FACC) and the American Heart Association (FAHA) and founding member of the Heart Failure Society of America. She served on the Executive Committees of both the Council on Clinical Cardiology and the Council on Basic Science of the AHA. Recent national leadership roles included the national Executive Committee of the Task Force on Clinical Competence of the ACC, AHA and American College of Physicians, a body which determines national standards for medical competency for novel cardiovascular technologies. She was also a member of the Consensus Conference Group on Professionalism and Ethics of the ACC and AHA. She continues to be an active invited lecturer at national professional meetings, as well as Harvard Law School and Harvard Medical School.

Dr. Lorell is a graduate of Stanford University, and she received her M.D. degree and her Residency in Internal Medicine from Stanford University Medical School. She received her advanced training as a Fellow in Cardiovascular Medicine at Harvard University. She is a Diplomate of the American Board of Internal Medicine, the Subspecialty Board of Cardiovascular Disease, and the Subspecialty Board of Interventional Cardiology. She is admitted to practice medicine in the states of California and Massachusetts. She is the author of over 160 medical science publications, 26 chapters and 2 books, including 8 recent publications in the area of health policy.

Brent Pawlecki, MD (Vice Chair)

Chief Health Officer, The Goodyear Tire & Rubber Comapny

Brent Pawlecki, MD serves as the Chief Health Office at Goodyear Corporation. Prior to joining Goodyear, Dr. Pawlecki was the Corporate Medical Director for Pitney Bowes Inc., overseeing all health related issues and services of the organization, including the Pitney Bowes' award-winning corporate clinics and wellness programs, and the Disability/Workers Compensation Department. Dr. Pawlecki initially joined Pitney Bowes as Associate Medical Director in 1999, and served as the Corporate Medical Director since 2007. In addition, he served as the corporate medical consultant and as Chief HIPAA Privacy Officer.

Dr. Pawlecki completed Undergraduate and Medical School at St. Louis University, St. Louis, Missouri. After finishing his residency in Internal Medicine and Pediatrics in Connecticut at Bridgeport Hospital/Yale University, Dr. Pawlecki worked in the Emergency Department. He entered private practice on Long Island, NY, serving as Medical Director of a multi-specialty group, and was instrumental in expanding the practice from one to five locations. He then began working as the Medical Director of Occupational Medicine for a public 70-site physician practice management group. Dr. Pawlecki initially joined Pitney Bowes as Associate Medical Director in 1999, and has served as the Corporate Medical Director since 2007.

He has completed the degree of Masters of Medical Management (MMM) at the University of Southern California’s Marshall School of Business. He is actively involved in numerous professional organizations, including the National Business Group on Health, New York Business Group on Health, and serves a Board member for the Campaign for Public Health.

Eve Slater, MD, F.A.C.C. (Vice Chair)

Associate Clinical Professor of Medicine, Columbia University College of Physicians & Surgeons

Dr. Eve Slater is an Associate Clinical Professor of Medicine at Columbia University College of Physicians & Surgeons. Additionally, she serves on the Boards of the University of Medicine and Dentistry of New Jersey (nominated); Idera Pharmaceuticals, Cambridge, MA; iTheRx, San Diego, CA; the Council of the Rockefeller University, New York City,, NY; and the Scientific Advisory Board of the Global Alliance for TB Drug Development, New York City, NY.

Dr. Slater’s career in medicine, science and public policy has spanned academics, business and government. Most recently she was Senior Vice President of Worldwide Policy at Pfizer, Inc., where she represented the pharmaceutical industry in health care reform with a special emphasis on coinsurance and medication adherence. She has served as Assistant Secretary of Health for the U.S. Department of Health and Human Services. Prior to joining HHS, she spent over 19 years with Merck in a number of critical scientific, strategy and public policy positions. In 1983, she joined the Merck Research Laboratories in biochemical endocrinology and molecular biology, and in 1988, she was promoted to head the regulatory affairs department as VP and later SVP of Clinical and Regulatory Development. In 2001, she was named as SVP of External Policy for Merck Research Laboratories, and VP of Merck Corporate Public Affairs. An expert on HIV treatment research, she served as a member of both the U.S. Keystone National Policy Dialogue on HIV and the NIH Office of AIDS Research Advisory Council. An expert on the FDA, she was named to the Subcommittee of the FDA Science Board in 2007.

In 2001, Dr. Slater was appointed by President George W. Bush as Assistant Secretary of Health, the first woman to hold this position. In this role, she served HHS Secretary Tommy Thompson as chief health policy advisor, with special emphasis on e-health and innovation, biosecurity, clinical subjects’ protection, women’s health, eldercare and HIV/AIDS. After leaving HHS, she became a director and advisor to a number of biotechnology companies, including Vertex Pharmaceuticals, Cambridge, MA and Phase Forward, Waltham, MA.

Dr. Slater received her B.A. from Vassar College (Phi Beta Kappa) and her M.D. from Columbia (Alpha Omega Alpha). She received her training in internal medicine and cardiology at the Massachusetts General Hospital, where she was the first woman named as Chief Resident in Medicine and later led the Hypertension Unit. She also served as Assistant Professor of Medicine at Harvard Medical School. A Fellow of the American College of Cardiology, she continues to serve patients as an Associate Attending Physician at NY Presbyterian Hospital and Associate Professor of Medicine at Columbia.

Justine Carr, MD

Chief Medical Officer, Steward Health Care System, LLC

Justine M. Carr, MD is Chief Medical Officer at Steward Health Care System. Steward is a clinically integrated network based in Boston with 10 hospitals in Eastern Massachusetts and more than 2,000 physicians. It is the second largest physician network in New England, serving over 1,200,000 patients annually. Steward is one of the 32 programs designated by CMS as a Pioneer Accountable Care Organization.

Dr. Carr is chair of the National Committee on Vital and Health Statistics (NCVHS), an 18 member committee advisory to the Secretary of Health and Human Services on health data strategy. She has been a member since 2004, serving also as co-chair of the NCVHS Quality Subcommittee. NCVHS holds hearings and makes recommendations to the Secretary in areas of population health, quality, data standards, administrative simplification and privacy.

Dr. Carr has participated in national and state initiatives related to health care quality and data stewardship, including American Health Information Community Quality Workgroup; Agency for Health Research and Quality (AHRQ) Composite Measures Work Group (Patient Safety Indicators and Quality Indicators); Center for Democracy and Technology--Uses of De-identified Data; Institute of Medicine Digital Learning Collaborative; and Massachusetts E-health Initiative Privacy and Security Ad Hoc Workgroup.

Dr. Carr is an internist and hematologist and formerly held assistant professor positions in Medicine, Surgery and Pathology at Harvard Medical School. Dr. Carr received her medical degree at Columbia College of Physicians and Surgeons and trained at Presbyterian Hospital, Massachusetts General Hospital and Beth Israel Deaconess Medical Center.

Michael F. Collins, MD

Chancellor, University of Massachusetts Medical School

Michael F. Collins, MD, a nationally respected education and health care policy advocate and leader of not for profit health care, was appointed Senior Vice President for Health Sciences at the University of Massachusetts and interim Chancellor of the University of Massachusetts Medical School in June of 2007.

Dr. Collins currently directs the University of Massachusetts system-wide health sciences efforts, charged with leading strategic initiatives to further the university's efforts in the Commonwealth's critical life sciences industry. As interim chancellor of the medical school, Dr. Collins, a Clinical Professor of Medicine, provides critical direction and leadership to the campus' continuing efforts to distinguish itself as a premier academic health sciences center of national distinction. Dr. Collins directs the campus' external outreach, focusing on expanding and enhancing relationships with the University Board, the UMass Memorial Health System, the community, the legislature and the philanthropic community. In addition, he provides guidance for institutional advancement and fundraising initiatives and administrative oversight and leadership for UMass Medical School enterprise operations, including Commonwealth Medicine and the Massachusetts Biologics Laboratories. Dr. Collins is also responsible for managing the institutional infrastructure, including oversight of finance and campus operations.

Dr. Collins was appointed chancellor of the University of Massachusetts Boston in 2005. In this role, he was charged with overseeing an institution renowned for its access to excellence and its diversity. The most diverse university in New England, the campus boasts a student population of 13,000, speaking over 90 languages. Chancellor Collins managed a university budget of $225 million and led an academic community of more than 800 full and part-time faculty. In the two years Chancellor Collins led UMass Boston, he initiated campus efforts to complete a strategic and master planning effort to increase enrollment, research support and philanthropic giving to garner local and national recognition for the UMass Boston programs; and, began much needed physical improvements to the campus.

Prior to joining UMass Boston, Dr. Collins served as president and chief executive officer of Caritas Christi Health Care System from 1994 to 2004. Under his leadership, Caritas Christi became the second-largest healthcare system in New England, generating more than $1.1 billion in annual revenues from six acute care hospitals, physician group practices, several extended care facilities and other healthcare entities, all located in eastern Massachusetts. From 1994 to 2001, Dr. Collins also served as president of St. Elizabeth's Medical Center in Brighton, a university academic medical center affiliated with Tufts University School of Medicine.

Karen Day

Executive Director, US Policy, AstraZeneca Pharmaceuticals LP

Karen Day is the Executive Director of US Public Policy at AstraZeneca Pharmaceuticals LP.

Stephen Evangelista

Chief Executive Officer, Arthritis Foundation New England Region

Steve is the Chief Executive Officer of the Arthritis Foundation New England Region. He has been with the Arthritis Foundation since 2001, most recently serving as President and CEO of the Northern and Southern New England Chapter. He was the 2005 recipient of the highly regarded Clifford Clarke Award for Outstanding Leadership.

Steve began his non-profit career in 1970 as the first Executive Director of the Rhode Island Special Olympics. In 1988, he was appointed to lead the Dole Foundation for the Employment of People with Disabilities in Washington, DC. In the early nineties, he assumed the role of Deputy Chair for Boy’s Town New England where he was instrumental in raising $20 million to build the Boy’s Town New England Campus in Portsmouth, Rhone Island. In 1994, Steve was appointed to President/CEO of the National Kidney Foundation for Massachusetts, Rhode Island, New Hampshire and Vermont. Steve received his BA from Roger Williams University and his MA from Rhode Island College. He has lectured at Brown University on the subject of Marketing Non-Profit Organizations.

Steve and his wife Arlene reside in Warwick, RI. They have four grown children and six grandchildren.

Donald J. Gudaitis

Chief Executive Officer, American Cancer Society - New England Division

Donald J. Gudaitis became the first Chief Executive Officer of the American Cancer Society’s New England Division when the six New England states merged in 1997. For the previous decade, he served as the Executive Vice President of the Society’s Massachusetts Division. He currently leads or serves on numerous national-level American Cancer Society strategic teams.

Before coming to New England, Mr. Gudaitis served as the Executive Vice President for the American Cancer Society’s former Delaware Division for two years, and before that, as an Area Director for the former New Jersey Division. A graduate of Dickinson College with a major in psychology, he has completed the core M.B.A. program at Rutgers University. In 1993, Mr. Gudaitis was named one of the Ten Outstanding Young Leaders by the Boston Jaycees.

Andy Hartsfield

Associate Vice President, US Public Policy, Sanofi

Andy Hartsfield is Associate Vice President, US Public Policy. In that role, he and his public policy team track and analyze federal and state public policy issues that could affect Sanofi, any of its business units, or the research-based pharmaceutical industry in general. Working with their federal and state government affairs colleagues, they develop proposals to shape public policy that would help Sanofi and its business units meet their strategic objectives to provide patients with meaningful solutions for their unmet medical needs.

Prior to joining Sanofi, Andy worked at GlaxoSmithKline for 20 years, from which he retired in 2011 as Vice President, Public Policy and Advocacy.

Before joining GlaxoSmithKline, Andy served chief legislative assistant for U.S. Senator Jesse Helms, with whom he worked for 6 years. Prior to that he served as counsel for the U.S. Senate Subcommittee on Security and Terrorism in Washington, D.C.

After graduating from Law School in 1980, Andy served four years on active duty in the U.S. Navy Judge Advocate Generals Corps.

Andy earned a Bachelor of Arts degree in chemistry in 1977 from the University of North Carolina at Chapel Hill and a law degree in 1980 from Wake Forest University School of Law in Winston-Salem, N.C.

A native of Wake Forest, N.C., Andy and his wife, Barbara, have two sons and a daughter.

Roberta Herman, MD

Chief Operating Officer, Harvard Pilgrim Health Care

Roberta Herman, M.D. is Chief Operating Officer for Harvard Pilgrim Health Care, one of New England’s largest non-profit managed health care organizations plans, providing care and coverage to over one million members throughout Massachusetts, Maine, and New Hampshire.

As Chief Operating Officer, Dr. Herman is responsible for the day-to-day operations of Harvard Pilgrim, including Sales, Marketing, Account and Member Services, Medical Management, the Harvard Pilgrim Institute as well as Product Development and the Provider Network. During the last two years Dr. Herman also oversaw Harvard Pilgrim’s Massachusetts Commercial Fully Insured line of business – a segment comprised of approximately 400,000 fully insured lives that is Harvard Pilgrim’s largest core line of business.

Before becoming COO, Dr. Herman served as Chief Medical Officer where she oversaw Harvard Pilgrim's clinical departments, including health promotion, disease management, pharmacy services, behavioral health, and quality and utilization programs. Under Dr. Herman’s leadership, Harvard Pilgrim was rated the #1 private health plan in America for seven consecutive years, according to an annual ranking of the nation’s best health plans by the National Committee for Quality Assurance (NCQA). She was also responsible for creating and implementing a ground-breaking Pay for Performance Program with Partners HealthCare as well as first-to-market predictive modeling program. Previously she served as Chief of Internal Medicine at Harvard Community Health Plan where she oversaw implementation of their first electronic medical record system. She has worked at Harvard Community Health Plan and then Harvard Pilgrim combined for more than 20 years.

Dr. Herman is a graduate of McGill University Medical School (Montreal, Canada). She completed her residency in Internal Medicine at the Royal Victoria Hospital (Montreal, Canada) and received a Masters equivalent degree in Epidemiology and Biostatistics from McGill University while doing a fellowship year in Community Medicine.

Kenneth I Kaitin, PhD

Professor and Director, Tufts Center for the Study of Drug Development, Tufts University

Dr. Kaitin has served as the Director of the Tufts Center for the Study of Drug Development since 1998. He is also a Professor at Tufts University School of Medicine. Dr. Kaitin is an internationally recognized expert on the science of drug development. He publishes extensively on the factors that contribute to the slow pace and high cost of pharmaceutical R&D and the impact of regulatory and legislative initiatives to speed new drug development and review. He also testifies in Congress on drug development issues and is frequently quoted in the business and trade press on R&D trends in the research–based pharmaceutical industry.

Dr. Kaitin is a former president of the Drug Information Association and editor–in–chief of the Drug Information Journal. He received a B.S. from Cornell University and an M.S. and Ph.D. in pharmacology from the University of Rochester.

Robert Mandel, MD, MBA

Chief Executive Officer, Health Dialog

Dr. Robert Mandel was named Chief Executive Officer of Health Dialog in January of 2013. Dr. Mandel has more than 15 years of senior leadership experience in health systems and health plan management. Prior to his role of Chief Executive Officer, he served as Chief Commercial Officer at Health Dialog. Before joining Health Dialog, Dr. Mandel served as Senior Vice President of Health Care Services for BlueCross BlueShield of Tennessee and Vice President of Health Care Services for BlueCross BlueShield of Massachusetts.

After attending Princeton University, Dr. Mandel received his Doctor of Medicine degree from the Johns Hopkins University School of Medicine in Baltimore. Dr. Mandel also holds a master’s degree in Business Administration from The Wharton School, University of Pennsylvania, in Philadelphia.

Dr. Mandel is a graduate of the AAHP Leadership Program, and a Fellow of the American College of Surgeons. He also holds membership in the American Academy of Ophthalmology and the American College of Physician Executives.

Gerald D. Maxwell, PhD

Associate Dean for Postdoctoral and External Affairs and Professor of Neuroscience, University of Connecticut Health Center

Gerald D. Maxwell, Ph.D. was appointed as the first Associate Dean for Postdoctoral and External Affairs at the University of Connecticut Health Center in 2007.

Prior to this appointment, Dr. Maxwell served as the Associate Dean of the Graduate School for the Health Center campus from 1992-2007. In that capacity he was responsible for programs leading to the Ph.D. in Biomedical Science, the Master of Public Health, and the Master of Dental Science degrees as well as combined degree programs including the M.D./Ph.D., D.M.D./Ph.D. and the M.D./M.P.H.

As a faculty member, Dr. Maxwell directed a National Institutes of Health-funded research program on the molecular and cellular analysis of peripheral nervous system development from 1980-2000. He currently focuses his efforts on academic administration, teaching, advising trainees, and external relations activities.

Dr. Maxwell is a graduate of Yale College and received his Ph.D. in developmental biology from the University of Oregon. He subsequently completed a postdoctoral research fellowship in developmental neurobiology at Harvard Medical School prior to joining the University of Connecticut Health Center faculty.

Julie H. McHugh

Chief Operating Officer, Endo Pharmaceuticals

Prior to joining Endo in 2010, Ms. McHugh was the CEO of Nora Therapeutics, Inc., a venture capital-backed biotech company focused on the treatment of infertility disorders. Prior to joining Nora Therapeutics, she was Company Group Chairman for Johnson & Johnson's Worldwide Virology Business Unit, which included oversight of a R&D portfolio including compounds for HIV, Hepatitis C, and Tuberculosis. Prior to her role as Company Group Chairman, Ms. McHugh was President of Centocor, Inc. a J&J subsidiary.

Ms. McHugh received a Bachelor of Science degree from Pennsylvania State University and her masters of business administration degree from St. Joseph’s University. She currently serves on the Board of Visitors for the Smeal College of Business of the Pennsylvania State University, the Board of Directors for the Nathaniel Adamczyk Foundation, and was 2009 Chairman of the Board of Directors for the Pennsylvania Biotechnology Association.

Robert A. McMahon

Leader of U.S. Policy and Government Relations, Merck & Co., Inc.

Robert A. McMahon (Bob) currently leads Merck & Co., Inc.'s U.S. Policy and Government Relations. Mr. McMahon and his team represent Merck in Washington, DC and are responsible for U.S. policy development and legislative advocacy on Merck's key federal issues. They also oversee the administration of the Merck PAC and the company’s grassroots program.

Throughout his 28 year career, Mr. McMahon has developed a reputation as a passionate, results-oriented leader with a keen ability to motivate a diverse employee population scattered throughout the nation. He is also known as a steadfast advocate of Merck's mission of putting patients first.

A CPA by training, Mr. McMahon began his Merck career in finance. Over the course of his long career, he has held a variety of commercial roles with both domestic and international responsibilities. Starting in 2000, Mr. McMahon served as Vice President and General Manager of Merck/Schering-Plough Pharmaceuticals where he guided the formation of a stand-alone joint venture between the two companies. In 2004, he was appointed Vice President, Marketing and Franchise Business Group Leader of the Arthritis and Analgesia Franchise where he led the most competitive therapeutic franchise in the U.S. In 2005, Mr. McMahon was appointed General Manager, U. S. Human Health, Hospital and Specialty Products and then became General Manager of the Cardiovascular/Metabolic Business Unit. In October 2007, Mr. McMahon was promoted to President, U. S. Pharmaceuticals and in August 2008, he assumed leadership of Merck's U.S. Commercial Operations.

Over the past several years, Mr. McMahon has been responsible for the development and implementation of an industry-leading new commercial model -- one of Merck's key strategic initiatives in the company's Plan to Win transformation. Implemented in early 2009, this new model was designed to respond to current and evolving trends in the healthcare environment and help Merck extend its leadership position in the industry by building trust and demonstrating value to all customer segments. While implementing this new model, Mr. McMahon also successfully executed the Merck-Schering Plough merger-related restructuring and integration of the U.S. Commercial Operations teams in early 2010 within 100 days of the merger completion.

Mr. McMahon is a graduate of Villanova University where he earned a Bachelor of Science degree in accounting. He began his career with Arthur Andersen & Co. in their New York Office. He also worked at the Squibb Corporation prior to joining Merck.

David P. Meeker, MD

President and Chief Executive Officer, Genzyme Corporation

David Meeker, 57, was appointed President and Chief Executive Officer of Genzyme in October 2011. Genzyme is a global biotechnology company committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs. Dr. Meeker oversees and provides the vision for the company’s two business units – Rare Diseases and Multiple Sclerosis – as well as its long-standing relationships with patient communities and dedicated workforce of 10,000 employees.

In his career with Genzyme, Dr. Meeker has held key positions of increasing responsibility, most recently as Chief Operating Officer. In this role, he was responsible for Genzyme’s commercial organization, overseeing its business units, country management organization, and global market access functions. As Chief Operating Officer, he played an important role in the integration with Sanofi.

Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of therapeutic products, including treatments in the current rare disease portfolio. As President of the Global Rare Disease Business, he oversaw the global launches of Aldurazyme®, Fabrazyme®, and Myozyme®.

Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters.

Dr. Meeker is a Board member of BIO, the Biotechnology Industry Organization. He is also a Board member of Prize4Life, an organization dedicated to accelerating the discovery of treatments for amyotrophic lateral sclerosis, as well as a Board member of the California Institute of Healthcare (CHI), an independent organization devoted to researching and advocating policy to forward the interests of California’s biomedical community.

Dr. Meeker received his M.D. from the University of Vermont Medical School. He completed an Internal Medicine residency at Beth Israel Hospital in Boston and a Pulmonary/Critical Care fellowship at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.

Alan Moses, MD

Corporate Vice President and Global Chief Medical Officer, Novo Nordisk Inc.

Alan Moses received a BS from Duke University and an MD from Washington University School of Medicine prior to training at Barnes Hospital in St. Louis, MO, the National Institutes of Health in Bethesda, MD, and Tufts-New England Medical Center in Boston.

Dr. Moses is board certified by the American Board of Internal Medicine and has subspecialty certification in Endocrinology and Metabolism. He is a Fellow of the American College of Physicians. In 1998, he was appointed Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center, a Harvard-affiliated independent clinical and research facility and was appointed to the rank of Professor of Medicine at Harvard Medical School in 2002. During his tenure at Harvard, Dr. Moses was involved in basic and clinical research, patient care, teaching of medical students, housestaff, and fellows, and medical research administration. He co-founded and co-directed the Clinical Investigator Training Program at Harvard Medical School and the Massachusetts Institute of Technology HST Program.

In April 2004, Dr. Moses joined Novo Nordisk, Inc as Associate Vice President for Clinical Research and Medical Affairs - Endocrinology and in 2007 was named Chief Medical Officer, North America. In January of 2008, he was named Corporate Vice President and Global Chief Medical Officer. In this role, he is involved in the full spectrum of the diabetes focus of Novo Nordisk from drug discovery, through drug development, brand messaging, and the implications of diabetes for the company and for patients, healthcare professionals and for healthcare systems.

He has written over 100 papers and articles on the treatment of diabetes, is an Editor of the Fourteenth edition of Joslin’s Diabetes Mellitus, and has been recognized both locally and nationally for clinical care in diabetes and for his research in diabetes and growth factors.

Vas Narasimhan, M.D. MPP

Global Head, Vaccines Development Novartis Vaccines & Diagnostics

Vas Narasimhan is Global Head, Vaccines Development for Novartis Vaccines and Diagnostics. In this role, he is responsible for the clinical development of Novartis industry leading vaccine pipeline with over 25 vaccine projects and nearly 100 global clinical trials ongoing annually.

Prior to assuming leadership of the Development organization in 2012, Vas was Head, Novartis Vaccines North America and US Country Head for Novartis Vaccines and Diagnostics, during which he drove strong growth in the region, building a fully integrated organization that successfully launched Menveo (MenACWY), created new seasonal flu distribution channels, and executed pandemic influenza programs. Previously, Vas served in roles of increasing responsibility at Novartis including as Vice President of US Marketing, Meningitis Franchise Head, Global Marketing, Menveo Brand Director and Head of Portfolio Strategy for the Office of the CEO at Novartis Pharma AG.

Prior to joining Novartis, Vas worked in the Pharmaceuticals and Medical Products Practice at McKinsey & Co., consulting major pharmaceutical and healthcare companies on a range of initiatives, including large-scale M&A activity and top-level corporate strategy.
Vas earned his medical degree from Harvard Medical School and obtained his MPP in International Health Care Policy from Harvard’s John F. Kennedy School of Government. He received his bachelor’s degree in Biological Sciences from University of Chicago.

Samuel Nussbaum, MD

Executive Vice President and Chief Medical Officer, Wellpoint, Inc.

Dr. Samuel Nussbaum is executive vice president, clinical health policy and chief medical officer for WellPoint, Inc. He oversees corporate medical policy, clinical pharmacy programs, programs in clinical excellence, and health information technology. His principal responsibilities include: serving as chief spokesperson and policy advocate on medical issues, guiding the corporate vision regarding quality of care and its measurements, leading efforts to assess clinical quality performance and safety and developing a strategy to foster further collaboration with physicians and hospitals and national organizations (such as CDC and FDA) to strengthen and improve patient care. Dr. Nussbaum also has responsibility for HealthCore, WellPoint’s clinical outcomes research subsidiary.

Dr. Nussbaum has served as president of the Disease Management Association of America, Chairman of the National Committee for Quality Health Care, as Chair of America's Health Insurance Plan's (AHIP) Chief Medical Officer Leadership Council and as a member of the AHIP Board, and currently serves on the National Quality Forum (NQF) Board and on the Secretary of Health and Human Services Advisory Committee on Genetics, Health, and Society. He received the 2004 Physician Executive Award of Excellence from the American College of Physician Executives and Modern Physician magazine. Dr. Nussbaum is professor of clinical medicine at Washington University School of Medicine and serves as adjunct professor at the Olin School of Business, Washington University.

Dr. Nussbaum served as executive vice president, Medical Affairs and System Integration, of the BJC Health Care, where he led integrated clinical services across the health system and served as President of its medical group.

Dr. Nussbaum earned his medical degree from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University Medical Center and Massachusetts General Hospital and in endocrinology and metabolism at Harvard and Massachusetts General Hospital, where he directed the Endocrine Clinical Group. Dr. Nussbaum served as a professor at Harvard Medical School where his clinical and basic research has led to new therapies to treat skeletal disorders and new technologies to measure hormones in blood.

Joshua Ofman, MD

Senior Vice President, Global Value and Access, Amgen Inc.

Joshua J. Ofman, MD, MSHS is senior vice president, Global Value and Access at Amgen. Dr. Ofman is responsible for directing Amgen activities related to global pricing, achieving coverage and reimbursement from national payers, coverage and payment policy, and oversight of evidence generation activities to demonstrate the economic value of Amgen products.

Dr. Ofman completed his undergraduate degree in the history and philosophy of science at University of California, Berkeley before completing his medical education at UC Irvine School of Medicine. He then completed his internship and residency in internal medicine at UCLA Medical Center. Following his residency, Dr. Ofman completed a two-year VA/UCLA/RAND fellowship in health services research, during which time he received his Masters of Science in Health Services (MSHS) degree from the UCLA School of Public Health. Dr. Ofman also completed a fellowship in gastroenterology at the UCLA integrated training program in digestive diseases. His research interests include health economics and technology assessment, program evaluation and health policy analysis, and he is widely published in these disciplines.

Dr. Ofman has served on several advisory boards for the American Gastroenterological Association, the American College of Physicians Clinical Efficacy Assessment Subcommittee, and is on the editorial board of the American Journal of Managed Care.

Prior to joining Amgen in 2003 as head of US Health Economics and Outcomes Research, Dr. Ofman was a member of the academic faculty in the Department of Medicine, UCLA School of Medicine, Cedars-Sinai Medical Center. Dr. Ofman also served as the Senior Vice President of Zynx Health Inc., a consulting company focused on evidence-based clinical information for quality improvement, and reimbursement and health economics strategy for life sciences companies.

James Roosevelt, Jr.

President and Chief Executive Officer, Tufts Health Plan

Mr. Roosevelt joined Tufts Health Plan in 1999 as senior vice president and general counsel and held that position until June 2005, when he became president and chief executive officer. As the general counsel, he presided over the legal department and the company's compliance, privacy and government relations functions.

Before joining Tufts Health Plan, Mr. Roosevelt was the associate commissioner for Retirement Policy for the Social Security Administration in Washington, D.C. He has also served as chief legal counsel for the Massachusetts Democratic Party and is co-chair of the Rules and By-laws Committee of the Democratic National Committee. Mr. Roosevelt spent 10 years as partner at Choate, Hall and Stewart in Boston. He is past chairman of the board of trustees for the Massachusetts Hospital Association, past president of the American Health Lawyers Association and past chairman of the board of trustees for Mount Auburn Hospital. Currently, Mr. Roosevelt serves as chairman of the board of directors for Massachusetts Association of Health Plans, and as a member of the board of directors at America’s Health Insurance Plans, Emmanuel College and the Kenneth B. Schwartz Center. He is also co-chair of the board of directors for the Tufts Health Care Institute. In November 2008, President-elect Barack Obama appointed Mr. Roosevelt to his transition team to co-chair a review of the Social Security Administration.

Mr. Roosevelt received his J.D. from Harvard Law School and his A.B. with honors in government from Harvard College. He has also completed the Advanced Management Program at Harvard Business School.

Brian Rosenfeld, MD

Executive Vice President and Chief Medical Officer, Philips-VISICU

Dr. Brian Rosenfeld is an Intensive Care Specialist who pioneered and developed the concept of remote intensive care unit management. He co-founded VISICU Inc. in 1998 with his partner Michael Breslow and served as its Executive Vice-President and Chief Medical Officer. The company had a successful IPO in 2006 and then was acquired by Royal Philips Electronics in 2008. He is currently responsible for devising the strategic direction of tele-health within Philips Patient Monitoring and Informatics.

Prior to founding VISICU, Dr. Rosenfeld was an Associate Professor of Anesthesiology and Critical Care Medicine, Medicine and Surgery at the Johns Hopkins University School of Medicine. While at Hopkins, he was Director of two critical care units and received the Shannon Award from the National Institutes of Health.

Murray N. Ross, Ph.D.

Vice President, Kaiser Foundation Health Plan and Director, Kaiser Permanente Institute for Health Policy

Murray Ross is Vice President, Kaiser Foundation Health Plan, and Director of the
Kaiser Permanente Institute for Health Policy in Oakland, California. His current work
focuses on how the U.S. health system can use new medical technologies more
effectively. Before joining Kaiser Permanente in 2002, Dr. Ross was an advisor to the
United States Congress. He served almost five years as the executive director of the
Medicare Payment Advisory Commission, a nonpartisan agency charged with making
recommendations on Medicare policy issues to the Congress. Previously, he spent nine
years at the Congressional Budget Office, lastly heading up the group charged with
assessing the budgetary impact of legislative proposals affecting Medicare and Medicaid.
Dr. Ross earned his doctorate in economics from the University of Maryland, College
Park, and completed his undergraduate work in economics at Arizona State University.
He enjoys running, writing, and traveling.

Lynn Taylor

Vice President, Government Affairs, EMD Serono Inc.

Lynn A. Taylor is Vice President of Government Affairs for EMD Serono, Inc. Ms. Taylor is responsible for all legislative, policy, and political activity for EMD Serono and for the oversight of the Washington, D.C. office. She is also responsible for building and solidifying relationships with key Federal and State government officials, policy makers and other key stakeholders for EMD Serono. Ms. Taylor guides the development of company positions related to key policy issues and legislation impacting the biopharmaceutical industry and EMD Serono’s business, products, policy and practices. She also serves as the chief liaison to major industry associations for the company, including the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO) and the Massachusetts Biotechnology Council (MBC). Ms. Taylor first joined the company in June 2005 as Executive Director of Government Relations.

Prior to joining EMD Serono, Ms. Taylor was Director, Federal Government Relations and Public Policy at Millennium Pharmaceuticals. Ms. Taylor also previously served as Director of Strategy and Health Policy at DEKA Research and Development and Director of Policy at PhRMA.

Ms. Taylor earned her master’s degree in public administration, with a concentration in policy analysis, from American University in Washington, D.C. and her bachelor’s degree in political science from Fordham University in New York.

David F. Torchiana, MD

Chairman and Chief Executive Officer, Massachusetts General Physicians Organization, Partners HealthCare System

In January 2003, Dr. Torchiana assumed the role of Chairman and Chief Executive Officer of the Massachusetts General Physicians Organization (MGPO). The MGPO, associated with the Massachusetts General Hospital, is a member of the Partners Health Care System and a teaching affiliate of the Harvard Medical School. The organization is a non-profit, tax-exempt corporation and the largest physician group practice in New England, representing more than 1,500 physicians.

Prior to his role at MPGO, Dr. Torchiana completed residencies in general surgery and cardiothoracic surgery at the MGH before joining the Department of Surgery there in 1989. He became Chief of Cardiac Surgery in 1998 and is an Associate Professor of Surgery at Harvard Medical School.

Dr. Torchiana graduated from Yale College in 1976. He spent the following year as a Churchill Scholar at Cambridge University, Cambridge UK, doing research in the Physiology Laboratory. He subsequently graduated from Harvard Medical School in 1981.

Delia Vetter

Senior Director of Benefits and Programs, EMC Corporation

As Senior Director of Benefits and Programs, Delia Vetter is responsible for creating and implementing benefits strategy development and execution, providing emerging healthcare technologies leadership, communications, systems, compliance, healthcare analytics, and administration for EMC’s organizations in the United States and Canada.

Since joining EMC Corporation in 1994, Delia has built a comprehensive benefits program focused on cost-effectiveness, innovative technologies, and health programs. She led the development of a cost containment health management strategy focused on employee consumerism, using leading edge technology to manage employee health and health care dollars, as well as to effect behavior modification.

Under Delia’s leadership, EMC was the first employer to provide an employer-sponsored ePersonal Health Record which serves as a model for other companies and agencies. EMC’s health management strategy has received numerous awards, including Massachusetts Technology Leadership, American Heart Association Fit Friendly Companies, Blue Cross Blue Shield Health Care Excellence, National Business Group on Health Healthy Companies, Massachusetts Corporate Citizenship in Public Health, and six Best Practices Awards from the New England Employee Benefits Council

Delia is a sought-after healthcare expert and has consulted employers, state, government, and education agencies looking to replicate EMC programs. In 2010, she was invited by the Office of Massachusetts Attorney General to present EMC’s HealthCare Strategy to their health care
leadership staff.

Actively involved in the healthcare marketplace, Delia serves on Advisory Councils, including the Pioneer Health Institute, the Employer Coalition in Healthcare, Blue Cross of Massachusetts, and Blue Health Intelligence Advisory Board. She also is a member of external boards, including Executive Committee member and Treasurer of Bridges of Excellence, Chairperson of the United Way Tri-Country, and board member of New England Health Institute and New England Employee Benefits Council.

Delia is a member of several organizations, such as Associated Industries of Massachusetts, the New England Health Institute Research and Policy Committee, the Human Resources Policy Association coalition on National Health Access, The Leapfrog Group, and The New England Employee Benefits Counsel.

Josef H. von Rickenbach

Chairman & Chief Executive Officer, PAREXEL International

As Chairman and CEO of PAREXEL, Mr. von Rickenbach has taken PAREXEL from its pioneering beginnings as one of the first clinical research organizations (CROs) more than two decades ago to its place as one of the top three public biopharmaceutical services companies today. He has led PAREXEL through its IPO, multiple public offerings, and over 30 acquisitions during the Company’s history of 28 years to expand its portfolio in order to meet changing client needs and market demand. Under his leadership, PAREXEL has evolved to provide a broad range of services to the biopharmaceutical industry, including integrated clinical development, regulatory affairs consulting, commercialization services and technologies that expedite time-to-market.

Foreseeing the globalization of clinical research, Mr. von Rickenbach has worked to expand PAREXEL’s global footprint to provide access to a wide array of geographies for clients’ programs. PAREXEL now operates in 70 locations throughout 54 countries, and has approximately 9,720 employees.

Mr. von Rickenbach has made several innovative contributions to the advancement of the biopharmaceutical services industry through PAREXEL, including conceiving of a complex, multi-disciplinary, systems-oriented approach to outsourced clinical development, bringing efficiencies, speed, scalability and standardization to the business. As part of the S-1 filing to the SEC, he was among the first to define the industry in formal terms. As the biopharmaceutical industry adopted information technology, Mr. von Rickenbach created a leading advanced technology offering, and today PAREXEL’s subsidiary Perceptive Informatics is a front runner in providing eClinical solutions.

Mr. von Rickenbach’s extensive experience in the biopharmaceutical services industries puts him at the forefront of drug development and management. After having begun his career with Schering-Plough, Mr. von Rickenbach also held positions with ENSECO (formerly ERCO).

Mr. von Rickenbach has served as Chair of the Association of Clinical Research Organizations (ACRO) and is a long-standing member of the ACRO Board of Directors. Mr. von Rickenbach is a key contributor to the New England business community, where PAREXEL’s global headquarters office is based. He serves on the Board of Directors of the New England Healthcare Institute and on the Health Policy and Management Executive Council of the Harvard School of Public Health. Mr. von Rickenbach previously won the Ernst & Young New England Entrepreneur of the Year Award, and has also served as a judge of the program.

Mr. von Rickenbach holds a B.S. degree in Business Economics from the School of Business at the Lucerne University of Applied Sciences in Switzerland, and a Master of Business Administration degree from Harvard University.

 
One Broadway, 15th Floor
Cambridge, MA 02142
phone icon  Phone:
(617) 225-0857
fax icon  Fax:
(617) 225-9025
email icon  Email:
info@nehi.net
Home   |   Directions   |   Contact Us   |   Privacy & Legal   |   RSS
© 2013 NEHI